Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of AG-120 or AG-221 plus standard chemotherapy in newly diagnosed IDH1/IDH2-mutant acute myeloid leukemia
NL-OMON60150Phase 1Active, not recruiting
- Sponsor
- Servier
- Start
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of ivosidenib and enasidenib in acute myeloid leukemia (AML) (2 arms), sponsored by Servier. Primary endpoint: Primary endpoint(s). Started Dec 2015; status: active, not recruiting.
02
Drugs
ivosidenibenasidenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON60150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60150.